This article is more than 5 years old. Information may no longer be current.

STAAR Surgical’s ICL sales up, revenue down

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

MONROVIA, Calif. — STAAR Surgical reported a net loss of $3.9 million in the second quarter of 2002, with revenues for the quarter decreased by 6.2% from the same quarter in 2001. Sales of the company's refractive product, the Implantable Contact Lens (ICL), increased 55% during the first half of the year in international markets, however. Company executives said they believe sales will continue to grow for the ICL as the product receives new approvals in Asia. Clinical trials of the ICL in Japan are expected to begin this quarter.

In other STAAR news, the company’s preclinical and manufacturing modules of its premarket application to the Food and Drug Administration for the ICL have been accepted. The FDA requires a 3-year follow-up of the patient cohort.

The company also announced it has hired Nicholas Curtis as senior vice president of sales and marketing. Mr. Curtis was a founding member of Chiron Vision and has worked for Allergan as well.